A composition for treating intestinal disorders in pets and its use

Abstract

The application discloses a composition for treating intestinal diseases of pets and application thereof, and the composition comprises the following components: a first component capable of ensuring sufficient intestinal endogenous enzymes; a second component composed of components capable of restoring intestinal flora balance; and a third component capable of consolidating the growth and reproduction effect of the second component in the intestine. The composition of the application is compounded by enzyme preparations, probiotics, nutritional additives and other functional components, and can restore the normal physiological functions of the intestinal tract of pets from multiple aspects, has a remarkable effect on treating diarrhea of pets, can obviously shorten the diarrhea process, improve the diarrhea degree, and fundamentally promote the recovery of the intestinal function of pets, and achieves a recovery effect.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of pet nutrition, in particular to a composition for treating intestinal diseases of pets and application thereof. BACKGROUND

[0002] With the improvement of people's living standards, raising pets has become a part of the lives of more and more people. However, pets, like humans or other animals, often suffer from diseases, and gastrointestinal diseases are common diseases in pets, commonly manifested as diarrhea. Diarrhea is a group of clinical syndromes caused by multiple pathogens and multiple factors, characterized by increased stool frequency and stool consistency, causing loss of appetite, rapid weight loss, dehydration, and electrolyte imbalance, and in severe cases, can cause poisoning symptoms and even death.

[0003] Currently, when pets have gastrointestinal diseases, the most commonly used treatment method is to take antibiotics. The widespread use of antibiotics in pet diseases can lead to drug resistance of pathogenic bacteria in the intestinal tract of pets and destruction of beneficial bacteria in the intestinal tract, causing intestinal flora imbalance. Antibiotics, whether for cause treatment or symptomatic treatment, cannot help the intestinal flora recover quickly, and cannot fundamentally solve the problem of gastrointestinal diseases. SUMMARY

[0004] The purpose of the present application is to overcome the above-mentioned defects existing in the prior art, and to provide a composition for treating intestinal diseases of pets, which can restore the normal physiological function of the pets by regulating the intestinal environment of the pets, maintain a healthy state, and fundamentally treat intestinal diseases of pets to achieve a cure effect.

[0005] To achieve the above-mentioned purpose, the technical solutions of the present application are as follows:

[0006] In a first aspect, the present application discloses a composition for treating intestinal diseases of pets, comprising the following components:

[0007] The first component can ensure sufficient endogenous enzymes in the intestinal tract.

[0008] The second component is composed of components capable of restoring the balance of intestinal flora; and

[0009] The third component can consolidate the growth and reproduction effect of the second component in the intestinal tract.

[0010] In some embodiments, the first component is an enzyme preparation selected from one or more of protease, saccharifying enzyme, and the protease is acid protease; the second component is probiotic bacteria; and the third component comprises at least one nutritional active ingredient.

[0011] In certain embodiments, the probiotic is selected from one or more of Bacillus licheniformis, Bacillus subtilis, Bacillus coagulans, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium bifidum, Lactobacillus casei.

[0012] In certain embodiments, the mass ratio of Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium bifidum, Lactobacillus casei is 1:1:1:1:1:1.

[0013] In certain embodiments, the third component comprises at least two nutritionally active ingredients.

[0014] In certain embodiments, the nutritionally active ingredients comprise probiotic nutritional additives and gut nutritional additives.

[0015] In certain embodiments, the probiotic nutritional additives are selected from one or more of glucose, xylo-oligosaccharides, fructo-oligosaccharides.

[0016] In certain embodiments, the gut nutritional additives are selected from one or more of glutamine, niacin, calcium pantothenate, vitamin B12.

[0017] In certain embodiments, soybean peptides, yogurt powder, malt dextrin, and silicon dioxide are also included.

[0018] In certain embodiments, the yogurt powder is fermented yogurt powder.

[0019] In certain embodiments, the third component comprises at least two nutritionally active ingredients.

[0020] The enzyme preparation: is respectively protease and saccharifying enzyme. Among them, the protease is acid protease, which can improve the digestion and absorption rate of protein components by animals, especially young animals, because the proteinase secretion system in the digestive tract of young animals is not well developed. In the middle and later stages of growth, although there are endogenous enzymes, they are still insufficient. When high-protein feeding is adopted, it is easy to cause diarrhea and other diseases due to poor protein digestion capacity, so adding acid protease can make up for this deficiency and reduce the probability of diarrhea. In addition, saccharifying enzyme can well solve the problem of undigested absorption of reverse amylopectin, increase the burden of the intestine, and rapidly decompose the reverse amylopectin to generate glucose by breaking the alpha-1,4-glucoside bond, which can be used for the growth and reproduction of probiotics.

[0021] Probiotics: According to the research on the biological components of the large intestine and small intestine of dogs and cats, the main components of the large intestine microorganisms are lactobacillus, bifidobacterium, bacillus, streptococcus and escherichia coli; the main components of the small intestine microorganisms are lactobacillus, bifidobacterium, bacillus, streptococcus and enterococcus. When the intestinal flora is unbalanced, the adverse effects caused by the unbalanced intestinal flora such as diarrhea can be alleviated by supplementing the microorganisms. The probiotics of the present application mainly include bacillus licheniformis, bacillus subtilis, bacillus coagulans, bifidobacterium breve, bifidobacterium longum, bifidobacterium bifidum, lactobacillus acidophilus, lactobacillus plantarum and lactobacillus casei. The contained bacterial composition is basically completely consistent with the original bacteria of the large intestine and small intestine of dogs and cats, and can restore the balance of intestinal flora and has obvious improvement effect on intestinal diseases.

[0022] Probiotic nutritional additives: Glucose, xylo-oligosaccharides and fructo-oligosaccharides can promote the growth, reproduction and metabolism of probiotics, provide nutrients for the proliferation of probiotics in the intestine, maintain the balance of intestinal flora, and have obvious improvement effect on intestinal diseases.

[0023] Intestinal nutritional additives: Glutamine, nicotinic acid, calcium pantothenate and vitamin B12.

[0024] Glutamine: Glutamine can maintain the structure and function of the intestinal barrier. Glutamine is an essential nutrient for the metabolism of intestinal mucosal cells, and plays a very important role in maintaining the integrity of the intestinal mucosal epithelial structure. Especially in the case of severe stress such as trauma, infection and fatigue, glutamine in the intestinal mucosal epithelial cells is quickly depleted. When the intestine lacks food, digestive juice or lacks glutamine, the intestinal mucosa atrophies, the villi become sparse and short, even fall off, the crypts become shallow, the intestinal mucosal permeability increases, and the intestinal immune function is impaired. Clinical practice has proved that the provision of glutamine by parenteral route can effectively prevent intestinal mucosal atrophy, maintain normal intestinal mucosal weight, structure and protein content, enhance intestinal cell activity, improve intestinal immune function and reduce the translocation of intestinal bacteria and endotoxins.

[0025] Nicotinic acid: When pets lack nicotinic acid, diarrhea occurs.

[0026] Calcium pantothenate: When pets lack calcium pantothenate, symptoms of gastritis, enteritis and intussusception of the gastrointestinal tract occur.

[0027] Vitamin B12: When the plasma concentration of pets is lower than the normal value, inflammatory intestinal diseases such as diarrhea occur.

[0028] Soybean peptide: white or yellow powder material prepared from soybean, soybean meal or soybean protein by enzymatic hydrolysis, containing polypeptide, small peptide and amino acid, as a hydrolysate of soybean protein, inheriting the advantages of protein nutrition. Soybean peptide is better absorbed than milk protein and amino acid, and is very easy to be absorbed by animals, suitable for animals with poor protein digestion and absorption. In addition, soybean peptide also has the effects of improving immunity and enhancing physical strength, and can quickly supplement protein source, eliminate fatigue and serve as a bifidobacterium proliferation factor.

[0029] Fermented yogurt powder: inoculated with probiotics in fresh milk, fermented and spray dried to prepare. The fermented yogurt powder contains a certain amount of probiotics, which is beneficial to the health of the intestinal tract, and the flavor of the fermented yogurt powder can mask the taste of the enzyme preparation and the probiotics, improving the palatability of the composition of the present application to pets.

[0030] In some embodiments, the composition comprises the following components in the following mass percentage: 1.5-2.5% protease, 1.5-2.5% glucoamylase, 1.5-2.5% soybean peptide, 0.1-0.3% Bacillus licheniformis, 0.02-0.08% Bacillus subtilis, 0.05-0.1% Bacillus coagulans, 0.005-0.025% Bifidobacterium breve, 0.005-0.025% Bifidobacterium longum, 0.005-0.025% Lactobacillus acidophilus, 0.005-0.025% Lactobacillus plantarum, 0.005-0.025% Bifidobacterium bifidum, 0.005-0.025% Lactobacillus casei, 0.5-1.5% glucose, 1-3% xylooligosaccharide, 1.5-4% fructooligosaccharide, 1-3.5% glutamine, 0.04-0.08% nicotinic acid, 0.03-0.08% calcium pantothenate, 0.005-0.025% vitamin B12, 40-50% fermented yogurt powder.

[0031] In a second aspect, the present application discloses a preparation method of the above-mentioned composition, comprising the following processes:

[0032] (1) Small material premixing: uniformly premixing glucoamylase, protease, probiotics, soybean peptide, glucose, xylooligosaccharide, fructooligosaccharide, nicotinic acid, calcium pantothenate, vitamin B12 and silicon dioxide;

[0033] (2) The small material after premixing is added to malt dextrin and yogurt powder according to the principle of equal amount increment, and then uniformly mixed and packed.

[0034] In the production of pharmaceuticals or food, due to the large difference in the proportion of each component in the formula, it is not easy to mix uniformly, therefore, the "equal amount increment method" is better. The specific operation method is: taking a small amount of components and an equal amount of large components, simultaneously placing them in a mixing machine to mix uniformly, then adding an equal amount of large components to the mixture to mix uniformly, and so on until all the large components are added.

[0035] Thirdly, the present invention discloses the use of the above-described composition or the composition prepared by the above-described preparation method in the preparation of a drug for treating non-infectious intestinal diarrhea in pets.

[0036] Fourthly, the present invention discloses the application of the above-described composition or the composition prepared by the above-described method in pet diarrhea.

[0037] When the above-mentioned raw materials are added to a composition for treating pet intestinal diseases in a specific ratio, the present invention has the following beneficial effects:

[0038] (1) This invention creatively adds an enzyme preparation to the composition to avoid diarrhea caused by insufficient endogenous enzymes. In addition, it adds essential nutrients for the intestines to avoid gastrointestinal diseases and diarrhea caused by insufficient intestinal nutrients and decreased intestinal immunity. Furthermore, it adds probiotics that are compatible with the original intestinal flora, which directly reach the intestines, restore the balance of intestinal flora, and significantly improve diarrhea. Finally, it adds nutrients that are conducive to the proliferation of probiotics to consolidate the growth and reproduction effect of probiotics in the intestines and avoid repeated diarrhea. This fundamentally solves the problem of diarrhea in pets.

[0039] (2) Since pet staple food is extruded puffed pellets, a certain proportion of starch must be added to achieve good puffing effect. However, heating starch under low temperature and high humidity conditions will cause irreversible gelation of the starch granule structure. After cooling, the gelled starch molecules recrystallize or reverse, and reversed amylopectin is difficult for the pet's body to absorb. This can cause sub-health or even more serious conditions in the pet's otherwise healthy or diseased intestines. The saccharifying enzyme added in this invention can effectively solve the problem of reversed amylopectin not being digested and absorbed, thus increasing the burden on the intestines. The saccharifying enzyme can rapidly decompose the α-1,4-glucosidic bonds of reversed amylopectin to generate glucose.

[0040] (3) The present invention adds probiotics that are compatible with the original intestinal flora, which can utilize the glucose generated by saccharifying enzymes to grow and multiply, restore the balance of intestinal flora, and significantly improve intestinal diseases. In addition, the extra addition of yogurt powder can utilize the Lactobacillus bulgaricus and Lactobacillus thermophilus in the yogurt powder, which can improve the utilization rate of nutrients in the yogurt powder, while inhibiting harmful bacteria and toxic substances, creating a good growth and reproduction environment for the added probiotics of the present invention, achieving twice the result with half the effort.

[0041] (4) This invention takes into account the occurrence of diarrhea, restores the normal physiological function of the pet's intestines from multiple aspects, and has a significant therapeutic effect on pet diarrhea. It can significantly shorten the diarrhea process, improve the degree of diarrhea, and fundamentally promote the recovery of the pet's intestinal function, so as to achieve a cure. DETAILED DESCRIPTION

[0042] The application will be further described in detail below with reference to examples.

[0043] Example 1

[0044] The total amount of raw materials is 1000g. Among them, protease 15g, glucoamylase 15g, soybean peptide 15g, bacillus licheniformis 1g, bacillus subtilis 0.2g, bacillus coagulans 0.5g, bifidobacterium breve 0.05g, bifidobacterium longum 0.05g, lactobacillus acidophilus 0.05g, lactobacillus plantarum 0.05g, bifidobacterium bifidum 0.05g, lactobacillus casei 0.05g, glucose 5g, xylo-oligosaccharide 10g, fructo-oligosaccharide 15g, glutamine 13.55g, nicotinic acid 0.4g, calcium pantothenate 0.8g, vitamin B12 0.25g, fermented yogurt powder 500g, malt dextrin 400g, silicon dioxide 8g.

[0045] The preparation method is specifically:

[0046] (1) Small material premix: glucoamylase, protease, probiotics, soybean peptide, glucose, xylo-oligosaccharide, fructo-oligosaccharide, nicotinic acid, calcium pantothenate, vitamin B12, and silicon dioxide are premixed uniformly;

[0047] (2) The small material after premixing is added to malt dextrin and yogurt powder according to the principle of equal increment, and then mixed uniformly and packaged.

[0048] Example 2

[0049] The total amount of raw materials is 1000g. Among them, protease 20g, glucoamylase 20g, soybean peptide 20g, bacillus licheniformis 2g, bacillus subtilis 0.4g, bacillus coagulans 0.95g, bifidobacterium breve 0.15g, bifidobacterium longum 0.15g, lactobacillus acidophilus 0.15g, lactobacillus plantarum 0.15g, bifidobacterium bifidum 0.15g, lactobacillus casei 0.15g, glucose 10g, xylo-oligosaccharide 20g, fructo-oligosaccharide 30g, glutamine 20g, nicotinic acid 0.65g, calcium pantothenate 0.5g, vitamin B12 0.1g, fermented yogurt powder 459.5g, malt dextrin 389g, silicon dioxide 6g, the raw material components are mixed uniformly according to the proportion, and the preparation method is the same as that of Example 1.

[0050] Example 3

[0051] The total amount of raw materials is 1000g. Among them, protease 25g, glucoamylase 25g, soybean peptide 25g, bacillus licheniformis 3g, bacillus subtilis 0.8g, bacillus coagulans 1g, bifidobacterium breve 0.25g, bifidobacterium longum 0.25g, lactobacillus acidophilus 0.25g, lactobacillus plantarum 0.25g, bifidobacterium bifidum 0.25g, lactobacillus casei 0.25g, glucose 15g, xylooligosaccharide 30g, fructooligosaccharide 40g, glutamine 35g, nicotinic acid 0.8g, calcium pantothenate 0.3g, vitamin B12 0.05g, fermented yogurt powder 493.55g, malt dextrin 300g, silicon dioxide 4g, the raw material components are mixed uniformly according to the proportion, and the preparation method is the same as that of example 1.

[0052] Example 4

[0053] 1 Clinical effect test

[0054] 1.1 Bed test of the composition prepared in example 1

[0055] 1.2 Test subjects

[0056] 1.2.1 Inclusion criteria

[0057] Inclusion criteria: (1) age between 1 month and 5 years old; (2) clear diagnosis according to medical history, clinical manifestations and related laboratory screening in accordance with the diagnostic criteria of non-infectious diarrhea.

[0058] Exclusion criteria: (1) infectious diarrhea caused by bacterial, viral, parasitic and other infectious factors, with symptoms such as fever; (2) severe diarrhea such as severe dehydration, shock or malnutrition; (3) heart, liver, kidney disease and other complications.

[0059] 1.2.2 General information

[0060] The test subjects were 106 cases of non-infectious diarrhea dogs and cats treated in the Teaching Animal Hospital Affiliated to Huazhong Agricultural University in Wuhan, Hubei Province, Aibido Pet Hospital in Taizhou, Zhejiang Province, and Anxin Pet Hospital in Dongguan, Guangdong Province from December 2019 to August 2020. According to the random number table method, they were divided into a control group and a test group. Among them, the control group had a total of 53 cases, including 24 dogs and 29 cats, aged 1 month to 5 years old; the test group had a total of 53 cases, including 25 dogs and 28 cats, aged 1 month to 5 years old; there was no significant difference (P>0.05) in breed, age, gender and other general information between the two groups. There was no statistically significant difference (P>0.05) in the number of stools and stool characteristics before treatment, and they were comparable.

[0061] 1.3 Methods

[0062] The control group of dogs and cats adopts basic treatment method, mainly including removing stimulating source, intravenous fluid supplement including correcting dehydration condition, electrolyte disorder, and adjusting diet mode. The test group is given the example on the basis, placed in a bowl to lick freely, or mixed with a small amount of dry food or canned food, or uses 40℃ or below cold boiled water to take, once a day in the morning and evening, ensures complete taking, the specific dosage is shown in Table 1. The stool frequency and stool character score of each group are recorded before treatment and 1d, 3d, 5d after treatment. The stool frequency recovery time, stool character recovery time and total effective rate of two groups are compared.

[0063] Table 1 Dosage table of example

[0064]

[0065] 1.4 Observation of symptoms and detection index

[0066] 1.4.1 Improvement of symptoms

[0067] The stool frequency and stool character score of each group are recorded before treatment and 1d, 3d, 5d after treatment. The stool character score standard: 0 points for formed stool, 1 point for paste-like stool, 2 points for between paste-like and water-like stool, and 3 points for water-like stool.

[0068] 1.4.2 Diarrhea stopping time and stool normal time

[0069] The diarrhea stopping time and stool normal time of two groups after starting treatment are recorded respectively.

[0070] 1.4.3 Evaluation of clinical curative effect

[0071] Curative effect standard: after 72h of treatment, the stool frequency and character of patients return to normal, and the clinical symptoms disappear, which is significant effect. After 72h of treatment, the clinical symptoms of patients are obviously improved, and the stool frequency and character are improved, which is effective. After 72h of treatment, the stool character, frequency and clinical symptoms of patients are not obviously improved, which is ineffective.

[0072] Effective rate=(significant effect+effective) / total number of cases x 100%.

[0073] 1.4.4 Observation of safety

[0074] The conditions of each patient before treatment and during treatment are observed, and whether there are adverse reactions such as vomiting and constipation is recorded.

[0075] 1.5 Statistical analysis

[0076] The data are analyzed by SPSS20.0 software. The measurement data are expressed as mean ± standard deviation Results are expressed as mean ± SD, n = 53, using independent t test; count data are expressed as percentages [n (%)] and compared using the χ2test. Differences were considered significant at P < 0.05 and highly significant at P < 0.01.

[0077] 2. Results and analysis

[0078] 2.1 Results of improvement of symptoms

[0079] 2.1.1 Results of improvement of stool frequency

[0080] As shown in Table 2, there was no significant difference in stool frequency between the control group and the test group before treatment (P > 0.05). After 1 day and 3 days of treatment, the difference was highly significant (P < 0.01), indicating that the antidiarrheal effect of the example on non-infectious diarrhea in dogs and cats was significantly better than that of the control method. After 5 days of treatment, the difference in stool frequency between the two groups was not significant (P > 0.05), and the average stool frequency in the test group was 1.92 times per day, while that in the control group was 2.04 times per day. This was because 87.5% of the cases could stop diarrhea and restore normal stool frequency within 5 days after clinical intervention.

[0081] Table 2 Analysis table of improvement of stool frequency in cases in the two groups (mean ± SD, n = 53)

[0082]

[0083] Note: The same column data marked with * indicates a significant difference (P < 0.05), and the same column data marked with ** indicates a highly significant difference (P < 0.01). The same as the following table.

[0084] 2.1.2 Improvement of stool character score

[0085] As shown in Table 3, there was no statistically significant difference in stool character score between the control group and the test group before treatment (P > 0.05). After 1 day and 3 days of treatment, the difference was highly significant (P < 0.01), indicating that the example could significantly improve the stool character of non-infectious diarrhea in dogs and cats.

[0086] Table 3 Analysis table of improvement of stool character score in cases in the two groups (mean ± SD, n = 53)

[0087] 2.2 Analysis of antidiarrheal time record

[0088] Table 4 Analysis table of antidiarrheal time record in cases in the two groups (mean ± SD, n = 53)

[0089]

[0090] In the experiment, the stool frequency and stool shape recovery time of the test group were significantly shorter than those of the control group (P<0.01), as shown in Table 4, which indicates that the example can greatly shorten the course of non-infectious diarrhea of dogs and cats, and relieve the diarrhea symptoms and degree.

[0091] 2.3 Comparison of clinical treatment effects of the two groups

[0092] Table 5 Analysis table of clinical treatment effect records of the two groups of cases (n=53, n(%))

[0093]

[0094] As shown in Table 5, among the 53 cases in the control group, the total effective rate was 81.13%; the total effective rate of the test group was 98.11% (P<0.01). It is indicated that the clinical effect of the example on non-infectious diarrhea of dogs and cats is significantly better than that of the basic clinical method, and the example has good clinical effect on treating non-infectious diarrhea of dogs and cats.

[0095] In summary, the composition of the example can restore the normal physiological function of the intestinal tract of pets from multiple aspects, has significant effect on treating diarrhea of pets, can significantly shorten the diarrhea process, improve the diarrhea degree, and fundamentally promote the recovery of the intestinal function of pets, and achieve the effect of recovery.

[0096] The above only describes some embodiments of the present application. For those skilled in the art, without departing from the concept of the present application, several modifications and improvements can be made, which all belong to the protection scope of the present application.

Claims

1. The use of a composition in the preparation of a drug for treating non-infectious intestinal diarrhea in pets, characterized in that, The composition comprises the following components in the following weight percentages: 1.5-2.5% acidic protease, 1.5-2.5% glucoamylase, 1.5-2.5% soybean peptide, 0.1-0.3% Bacillus licheniformis, 0.02-0.08% Bacillus subtilis, 0.05-0.1% Bacillus coagulans, 0.005-0.025% Bifidobacterium breve, 0.005-0.025% Bifidobacterium longum, 0.005-0.025% Lactobacillus acidophilus, and 0.005-0.0% [unclear - possibly a specific ingredient or ingredient]. 25% Lactobacillus plantarum, 0.005-0.025% Bifidobacterium bifidum, 0.005-0.025% Lactobacillus casei, 0.5-1.5% glucose, 1-3% xylooligosaccharides, 1.5-4% fructooligosaccharides, 1-3.5% glutamine, 0.04-0.08% niacin, 0.03-0.08% calcium pantothenate, 0.005-0.025% vitamin B12, 40-50% fermented yogurt powder, 30-40% maltodextrin, and 0.4-0.8% silicon dioxide; Wherein: the mass ratio of Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium bifidum, and Lactobacillus casei is 1:1:1:1:1:1; The saccharifying enzyme can reverse the reaction of amylopectin, breaking down α-1,4-glucosidic bonds to produce glucose.

2. An application as described in claim 1, characterized in that, The method for preparing the composition, Includes the following processes: (1) Premixing of ingredients: Premix the saccharifying enzyme, acidic protease, probiotics, soybean peptides, glucose, xylooligosaccharides, fructooligosaccharides, glutamine, niacin, calcium pantothenate, vitamin B12 and silicon dioxide evenly. (2) The premixed ingredients are added to the maltodextrin and yogurt powder according to the principle of equal increments and then mixed evenly before being packaged.

Images